Browsing Tag
Pancreatic Cancer
37 posts
Avacta (AIM: AVCT) opens AVA6103 Phase 1: Can sustained-release engineering salvage exatecan’s clinical legacy?
Avacta Therapeutics opens Phase 1 enrollment for AVA6103 exatecan PDC at two US oncology centers. Early data expected H2 2026. Read what it means for AVCT investors.
Could a proenzyme therapy disrupt chemotherapy’s dominance in pancreatic cancer treatment?
Can Propanc Biopharma’s PRP therapy reshape pancreatic cancer treatment? Discover what the biotech’s metastasis-focused strategy could mean for oncology.
How orphan drug status and patent protection shape Ampligen’s commercial and regulatory outlook
Discover how orphan drug status and long-dated patents could shape Ampligen’s regulatory path and commercial value in pancreatic cancer.
How a proenzyme-based approach from Propanc Biopharma tests the limits of current solid tumor paradigms
Can a proenzyme therapy reshape solid tumor treatment models? Explore what Propanc Biopharma’s PRP strategy signals for oncology markets.
Can Partner Therapeutics’ zenocutuzumab-zbco deliver a first-line breakthrough in NRG1+ lung cancer?
Zenocutuzumab-zbco by Partner Therapeutics shows durable first-line response in NRG1+ NSCLC. Find out what the new eNRGy trial data means for patients.
Next-gen RNA therapy SIL204 passes key safety milestone as Silexion Therapeutics prepares Phase 2/3 pancreatic cancer study
Find out how Silexion Therapeutics is advancing SIL204 after a key safety milestone in pancreatic cancer research.
Breakthrough allogeneic immunotherapy from Lunai Bioworks eliminates pancreatic tumors in preclinical study
Find out how Lunai Bioworks’ engineered dendritic-cell therapy achieved complete regression of pancreatic cancer in preclinical models and what it means for solid-tumor immunotherapy.
Inside Azenta’s partnership with the PRECEDE Foundation driving breakthroughs in early pancreatic cancer diagnostics
Discover how Azenta Life Sciences and the PRECEDE Foundation are building a global biobanking network to transform early pancreatic cancer detection.
N2OFF enters cancer-drug discovery market through MitoCareX merger
Find out how N2OFF’s merger with MitoCareX is reshaping its business and targeting pancreatic & lung cancers!
Radiopharm Theranostics (ASX: RAD) crashes 21.6% despite A$40m capital raise and clinical milestones
Radiopharm Theranostics shares fall 21.6% after A$40m raise, but strong clinical updates and Lantheus support point to long-term upside. Read the full investor breakdown.